|
|
1405 Parc-Technologique Blvd.
Quebec, QC G1P 4P5 Canada
phone:(418) 652-8525
fax:(418) 652-0881
|
|
| Symbol |
AEZS |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
150 |
|
|
| www.aeternazentaris.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Biopharmaceuticals for oncology and endocrinology |
|
| Management |
| Dr. Eric Dupont, Ph.D., Executive Chairman of the Board; Gilles R. Gagnon, M.Sc., M.B.A., President and Chief Executive Officer; Prof. Dr. Jurgen Engel, Ph.D., Executive Vice President, Global Research & Development; Dennis Turpin, CA, Vice President and Chief Financial Officer; Mario Paradis, CA, Vice President, Finance & Administration and Corporate Secretary; Dr. Eckhard Gunther, Ph.D., Vice President, Drug Discovery, AEterna Zentaris Inc.; Dr. Matthias Rischer, Ph.D., Vice President, Pharmaceutical Development, AEterna Zentaris Inc.; Dr. Manfred Peukert, MD, Vice President, Medical Affairs, AEterna Zentaris Inc.; Matthias Seeber, M.B.A., Managing Director, Zentaris GmbH |
| |
|
|
|
|
|
|
|
| Keywords |
| oncology, endocrinology, pharmaceuticals |
|
|
|
| Description |
|
AEterna Laboratories, Inc. holds a comprehensive portfolio of biopharmaceuticals for applications in oncology and endocrinology, ranging from pre-clinical products to products long established on the market. Using its library of 120,000 compounds, the company executes its research and development efforts in its proprietary drug discovery unit. |
|
| Products / Services |
AEterna's focus is on developing and marketing its luteinizing hormone-releasing hormone (LHRH) antagonist treatments. Cetrotide (R) (cetrorelix acetate), on the European market since 1999 and launched in the United States in 2001, is used to prevent premature ovulation in women undergoing in-vitro fertilization (IVF). AEterna is currently conducting clinical trials to determine the therapeutic effects of Cetrorelix (cetrorelix pamoate) in patients with benign prostatic hyperplasia (BPH) and endometriosis. Ozarelix is in Phase 2 clinical trials for use in tumor therapy as well as BPH. AEterna's other products include the orally-administered Perifosine, which slows the proliferation of various cancers by inhibiting the signaling peptide Akt.
|
|
| Technology / Differentiation |
| LHRH is naturally produced in the brain to control the secretion of luteinizing hormone (LH), which then regulates ovulation and egg maturation in women. Cetrotide (R) binds to LHRH receptors, slowing the release of LH and delaying the LH surge (by up to four days) that stimulates ovulation before the patient's ova can be retrieved for IVF. Treatment with this product can be accomplished within one monthly cycle with few injections and adjustable dosing. Cetrorelix and Ozarelix serve similar functions in men with prostate conditions; these products bind to LHRH receptors, rapidly suppress testosterone production and slow the proliferation of prostate cells. These therapies, unlike LHRH agonists, do not cause the preliminary hormone surge associated with significant side effects. Ozarelix is a controlled aggregate of the LHRH antagonist peptide in saline formulation, which provides a simple cost-effective production cost. |
|
| Market / Customers |
Infertility affects about 7.3 million women (12% of the reproductive age population) and their partners in the U.S., according to the 2002 CDC National Survey of Family Growth. Nearly 500,000 babies have been born in the United States via IVF and other Assisted Reproductive Technologies from 1985 to 2006. The combined total sales of contraceptives and infertility management products are expected to increase at a compound annual rate of 4.5%, reaching approximately $3.5 billion per year by 2010. Additionally, BPH treatment represents a growing market with more than 100 million men worldwide estimated to suffering from its symptoms. Prostate cancer will cause 28,660 deaths and 186,320 men be diagnosed with this condition in 2008.
|
|
| Competitors / Substitutes / Alternatives |
Entremed Inc (ENMD) Imclone Systems Inc (IMCL)
|
|
| Status |
| Cetrotide (R) is currently approved for use in eighty countries. The company's third quarter highlights, announced in November 2008, include: the completion of patient recruitment for its second efficacy trial of the Phase 3 program in benign prostatic hyperplasia (BPH) with cetrorelix, the signing of a license and cooperation agreement for the commercialization of cetrorelix and ozarelix in BPH with Handok Pharmaceuticals Co., Ltd. for the Korean market., the start of the second stage of recruitment for the Phase 2 trial in ovarian cancer with AEZS-108, and recovery of worldwide rights from Ardana plc for the Growth Hormone Secretagogue (GHS) compound, AEZS-130. Future development options are currently being evaluated for the use of this compound in growth hormone deficiencies. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
